ISOTRETINOIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for isotretinoin and what is the scope of freedom to operate?
Isotretinoin
is the generic ingredient in nine branded drugs marketed by Sun Pharm Inds Inc, Sun Pharm, Hoffmann La Roche, Mylan Pharms Inc, Teva Pharms Usa, Actavis Labs Fl, Amneal Pharms Ny, Aurobindo Pharma, Upsher Smith Labs, Zydus Pharms, Sun Pharm Inds Ltd, and Dr Reddys Labs Ltd, and is included in sixteen NDAs. There are two patents protecting this compound and five Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Isotretinoin has seventeen patent family members in nine countries.
There are thirteen drug master file entries for isotretinoin. Twelve suppliers are listed for this compound.
Summary for ISOTRETINOIN
International Patents: | 17 |
US Patents: | 2 |
Tradenames: | 9 |
Applicants: | 12 |
NDAs: | 16 |
Drug Master File Entries: | 13 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 146 |
Patent Applications: | 7,700 |
Drug Prices: | Drug price trends for ISOTRETINOIN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ISOTRETINOIN |
What excipients (inactive ingredients) are in ISOTRETINOIN? | ISOTRETINOIN excipients list |
DailyMed Link: | ISOTRETINOIN at DailyMed |
Recent Clinical Trials for ISOTRETINOIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Insel Gruppe AG, University Hospital Bern | Phase 2 |
Chang Gung Memorial Hospital | Phase 1/Phase 2 |
South Valley University | N/A |
Pharmacology for ISOTRETINOIN
Drug Class | Retinoid |
Medical Subject Heading (MeSH) Categories for ISOTRETINOIN
Anatomical Therapeutic Chemical (ATC) Classes for ISOTRETINOIN
Paragraph IV (Patent) Challenges for ISOTRETINOIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ABSORICA | Capsules | isotretinoin | 25 mg | 021951 | 1 | 2016-05-16 |
ABSORICA | Capsules | isotretinoin | 35 mg | 021951 | 1 | 2015-11-25 |
ABSORICA | Capsules | isotretinoin | 10 mg | 021951 | 1 | 2013-06-20 |
ABSORICA | Capsules | isotretinoin | 20 mg | 021951 | 1 | 2013-01-07 |
ABSORICA | Capsules | isotretinoin | 40 mg | 021951 | 1 | 2012-12-31 |
US Patents and Regulatory Information for ISOTRETINOIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-004 | Nov 5, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-005 | Nov 5, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Actavis Labs Fl | ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 205063-005 | Mar 31, 2021 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal Pharms Ny | ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 207792-003 | Sep 29, 2017 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan Pharms Inc | AMNESTEEM | isotretinoin | CAPSULE;ORAL | 075945-002 | Nov 8, 2002 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma | ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 218194-002 | Jan 29, 2024 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus Pharms | ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 211568-001 | Aug 29, 2023 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ISOTRETINOIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-004 | Mar 28, 1983 | ⤷ Sign Up | ⤷ Sign Up |
Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-001 | May 25, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-004 | May 25, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-005 | Aug 15, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-006 | Aug 15, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ISOTRETINOIN
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2963206 | ⤷ Sign Up | |
South Africa | 201700843 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | ⤷ Sign Up |
Brazil | 112017006779 | ⤷ Sign Up | |
Russian Federation | 2017106013 | ⤷ Sign Up | |
Brazil | 112017001963 | ⤷ Sign Up | |
Japan | 2017521470 | イソトレチノインの経口医薬組成物 | ⤷ Sign Up |
European Patent Office | 3200877 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.